Concepedia

Annie Arguello

AA

9

Publications

723

Citations

9

H-Index

2013

Active since

Affiliations

Denali Therapeutics (United States)(Current)

University of California, San Francisco

Annie Arguello is an author at Denali Therapeutics (United States) specializing in medicine, neuroscience, and neurology.

ORCID

Top concepts

Publications per year

2013–2024

9

Publications

9

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Danna Jennings, Sarah Huntwork‐Rodriguez, Anastasia G. Henry et al. · Science Translational Medicine · 2022 · 230 citations

Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice

Julie C. Ullman, Annie Arguello, Jennifer A. Getz et al. · Science Translational Medicine · 2020 · 194 citations

, , +15

Molecular architecture determines brain delivery of a transferrin receptor–targeted lysosomal enzyme

Annie Arguello, Cathal Mahon, Meredith Calvert et al. · The Journal of Experimental Medicine · 2021 · 80 citations · Full text

, , +22

Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes

Jing Guo, Dylan Braun, Gabriel A. Fitzgerald et al. · Cell · 2024 · 63 citations · Full text

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10

Xiang Wang, Elvira Negrou, Michael T. Maloney et al. · Scientific Reports · 2021 · 58 citations · Full text

Rows per page

1–5 of 9